CSL Behring Receives EU Orphan Drug Designations For RVIIa-FP For Hemophilia A And B Treatment
Links shared publicly online about this topic.
- 251total visits
CSL Behring Receives EU Orphan Drug Designations For RVIIa-FP For Hemophilia A And B Treatment
CSL Behring announced that it has been granted Orphan Drug Designations (ODD) by the European Commission for the development of its recombinant fusion protein linking coagulation factor VIIa with
View full resource at medicalnewstoday.com
Tags: Hemophilia, Protein, Drug, NovoSeven, CSL
Most Recently Shared on June 1, 2011 at 8:37 am By:
CSL Behring Receives EU Orphan Drug Designations For RVIIa-FP For Hemophilia A And B Treatment: CSL Behring announced .. http://dld.bz/abP32
Also Shared By:
Advertisement
MNT Drug Approvals
@mnt_drugapprov
CSL Behring Receives EU Orphan Drug Designations For RVIIa-FP For Hemophilia A And B Treatment http://mnt.to/3Wzg #regulatory
1 year ago...